Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier:
NCT00071097
First received: October 10, 2003
Last updated: September 19, 2016
Last verified: September 2016